The effectiveness of levofloxacin in prevention of febrile episodes in non-Hodgkin lymphoma patients receiving R-CHOP
Phase 3
Recruiting
- Conditions
- Febrile episode in non-Hodgkin lymphomaFebrile episodeNon-Hodgkin lymphomaLevofloxacinR-CHOP
- Registration Number
- TCTR20230719005
- Lead Sponsor
- Ratchadapisek Research Funds
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 72
Inclusion Criteria
Non-Hodgkin lymphoma patients confirmed by pathology
Age 18 years old or more
Receive R-CHOP regimen
Exclusion Criteria
Refuse to treatment/not consent
History of fluoroquinolone allergy
Epilepsy
QT prolongation on ECG
History of serious adverse events from fluoroquinolone
unable to follow up
active infection or documented fever
previous antibiotics within 5 days before enrollment
pregnancy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Febrile episode within 120 days Core Body temperature
- Secondary Outcome Measures
Name Time Method Septic shock rate within 120 days septic shock event,Infection-related mortality and all-cause mortality within 120 days death,Chemotherapy reduction rate and relative dose intensity end of R-CHOP 6 cycles event of chemotherapy reduction, RDI,Composite outcome of septic shock rate, chemotherapy dose reduction rate, infection-related mortality and all-cause mortality within 120 days Summation of each events,Onset of first febrile episode within 120 days time to first febrile episode